Aztreonam

證據等級: L5

預測適應症: 10 個

Aztreonam: From Gram-Negative Infections to Gonococcal Urethritis

One-Sentence Summary

Aztreonam is a monobactam antibiotic used against aerobic gram-negative bacterial infections. Among 10 TxGNN-predicted indications, Gonococcal Urethritis is the only candidate with meaningful evidence, supported by 1 completed clinical trial and 8 publications (including 1 RCT). The remaining 9 candidates — including the model's top-scored prediction, hyperamylasemia — lack any mechanistic or empirical support and are flagged Hold.

Quick Overview

Item	Content
Original Indication	Not confirmed via local licensing data; per general pharmacology, aztreonam is indicated for infections caused by aerobic gram-negative bacteria
Predicted New Indication	Gonococcal Urethritis
TxGNN Prediction Score	99.59%
Evidence Level	L2
Norway Market Status	Not marketed (未上市)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Note on ranking: The evidence pack's top-ranked prediction (hyperamylasemia, score 99.73%) and ranks 2–3, 5–7, 9–10 are all annotated by the repurposing rationale as having no mechanistic link and no clinical/literature support (Hold, L5). This report focuses on Gonococcal Urethritis (rank 4), the only candidate with real-world evidence, and briefly notes Epiglottitis (rank 8, L4, Research Question) as a secondary signal worth monitoring.

Why is This Prediction Reasonable?

Currently, no formal MOA record is available in the evidence pack (DrugBank MOA field: Data Gap). Based on known pharmacology, aztreonam is a monobactam antibiotic that selectively binds to Penicillin-Binding Protein 3 (PBP3) of gram-negative bacteria, inhibiting bacterial cell wall synthesis. Its spectrum of activity is limited to aerobic gram-negative organisms, with negligible activity against gram-positive bacteria or anaerobes.

Neisseria gonorrhoeae is a gram-negative diplococcus, placing gonococcal urethritis squarely within aztreonam's known antibacterial spectrum. This is therefore not a novel mechanistic inference by TxGNN, but a direct extension of an established antibacterial spectrum — the model has essentially rediscovered a pharmacologically expected relationship. This is further reinforced by clinical context: the CDC has identified antimicrobial-resistant N. gonorrhoeae as a top public health threat, since ceftriaxone (a third-generation cephalosporin) is now nearly the only reliably effective first-line agent. Repurposing older, underused antibiotics like aztreonam has been explicitly proposed in the literature as a strategy to expand treatment options against resistant gonorrhea, including for pharyngeal infection sites that are harder to eradicate.

By contrast, several other TxGNN-flagged candidates are mechanistically implausible — for example, Ureaplasma urethritis is caused by cell-wall-deficient organisms (Mycoplasmataceae), against which a cell-wall synthesis inhibitor like aztreonam should theoretically have no effect. This illustrates the importance of evidence-level triage rather than acting on TxGNN scores alone.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03867734	Phase 2/3	Completed	32	Single-arm, open-label demonstration study of aztreonam for pharyngeal gonorrhea, conducted in response to CDC's identification of antimicrobial-resistant N. gonorrhoeae as an urgent threat; evaluated an older, underused antibiotic as a potential new option given increasing resistance to first-line cephalosporins

Literature Evidence

PMID	Year	Type	Journal	Key Findings
3095216	1986	RCT (single-dose)	Genitourinary Medicine	Single 1g IM dose of aztreonam cleared infection in 61 men and 26 women at nearly all sites; well tolerated, effective against both penicillin-sensitive and penicillinase-producing strains
11406757	2001	Review/Surveillance	J Infect Chemother	Reviews emergence of cephem/aztreonam-resistant N. gonorrhoeae not mediated by beta-lactamase; notes no clinical treatment failures with third-generation cephems and aztreonam had been reported to date
33077658	2020	Cohort (single-arm, open-label)	Antimicrob Agents Chemother	Single-dose IM aztreonam (2g) trial in men, conducted to identify new gonorrhea treatment options amid ceftriaxone-resistance concerns; emphasizes need for regimens effective at the pharynx
3937450	1985	Cohort	Hinyokika Kiyo	Japanese epidemiologic and one-shot therapy study of aztreonam for gonorrheal infections; reports resistance rates among clinical isolates
6225808	1983	Cohort	J Infect Dis	Demonstrates aztreonam effectiveness against penicillinase-producing, penicillin-resistant gonococci amid rising global PPNG prevalence
6438364	1984	Cohort	Jpn J Antibiot	Bacteriological and clinical evaluation of aztreonam in 30 men with gonorrheal urethritis, including PPNG and non-PPNG strains
3157346	1985	Cohort	Antimicrob Agents Chemother	1g IM aztreonam compared with spectinomycin for uncomplicated gonorrhea; no treatment failures with either drug across urethral, rectal, and endocervical sites
6226596	1983	Cohort	G Ital Dermatol Venereol	Italian study of aztreonam in patients with acute gonococcal urethritis (abstract not available)

Norway Market Information

Aztreonam is currently not marketed in Norway, and no authorization records are available in this evidence pack.

Safety Considerations

Please refer to the package insert for safety information. No structured warnings, contraindications, or drug-drug interaction data are currently available in the evidence pack (DDI query status: not found).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Gonococcal urethritis is the only TxGNN-predicted indication in this evidence pack supported by direct mechanistic rationale (gram-negative spectrum match), a completed Phase 2/3 clinical trial, and an RCT alongside multiple decades-old cohort studies. This is a plausible, evidence-backed repurposing candidate — but the supporting trial (n=32) is small and single-arm, and most supporting literature predates modern resistance patterns, so guardrails are warranted before advancing further.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain TFDA/local regulatory label warnings and contraindications — required before any S1 safety pre-assessment can proceed
Resolve DG002 (High): obtain formal DrugBank MOA record to confirm mechanistic analysis
Since the drug is not currently marketed in Norway, assess import/registration pathway feasibility
Given the small, single-arm nature of the primary trial, consider whether additional confirmatory data (e.g., larger RCTs, current resistance surveillance) exists before clinical use is considered
Secondary signal for monitoring: Epiglottitis (rank 8, L4, Research Question) — mechanistically plausible (H. influenzae, gram-negative) but only supported by non-specific gram-negative infection case series; not yet actionable
Deprioritize: Ranks 1–3, 5–7, 9–10 (including the top TxGNN score, hyperamylasemia) — explicitly flagged as lacking mechanistic or empirical support; no further action recommended at this time
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.